← Back to Search
Anti-tumor antibody
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
Park Ridge, IL
Phase 2
Waitlist Available
Led By Rita Nanda, MD
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.
See full description
Eligible Conditions
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Progression Free Survival
Secondary study objectives
BRCA1 gene
Response Rate
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Carboplatin + AvastinExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
FDA approved
Bevacizumab
FDA approved
Find a Location
Closest Location:Oncology Specialists· Park Ridge, IL
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,077 Previous Clinical Trials
841,811 Total Patients Enrolled
26 Trials studying Breast Cancer
4,759 Patients Enrolled for Breast Cancer
Genentech, Inc.Industry Sponsor
1,576 Previous Clinical Trials
571,054 Total Patients Enrolled
97 Trials studying Breast Cancer
23,162 Patients Enrolled for Breast Cancer
Rita Nanda, MDPrincipal InvestigatorUniversity of Chicago
3 Previous Clinical Trials
111 Total Patients Enrolled
3 Trials studying Breast Cancer
111 Patients Enrolled for Breast Cancer